Clinical Trial Update: ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MASE-T (ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells) for metastatic melanoma has been terminated, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• MASE-T

Snippet

Sponsor: Inge Marie Svane | Conditions: Malignant Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2025-07-25